Literature DB >> 14691917

KIT 1530ins6 mutation defines a subset of predominantly malignant gastrointestinal stromal tumors of intestinal origin.

Jerzy Lasota1, Janusz Kopczynski, Maarit Sarlomo-Rikala, Regine Schneider-Stock, Tomasz Stachura, Radzislaw Kordek, Michal Michal, Carsten Boltze, Albert Roessner, Jerzy Stachura, Markku Miettinen.   

Abstract

Gastrointestinal stromal tumors (GISTs) are the most common mesenchymal tumors of the gastrointestinal tract. GISTs express KIT and show gain-of-function KIT mutations. Most of these mutations affect the KIT juxtamembrane domain, but other KIT domains are mutated at a lower frequency. In this study, frequency of GCC TAT insertion mutation (1530ins6) in KIT exon 9 (extracellular domain) and its possible clinicopathologic significance was investigated. Screening of 520 GISTs identified 26 cases with 1530ins6 KIT mutation and confirmed the previously reported low frequency of this type of KIT mutation among GISTs of different locations. Of the 26 tumors with 1530ins6 KIT mutation studied, 21 originated from the small intestine, 1 from the colon, and 3 from the rectum. In 1 case, primary small intestinal versus colonic localization could not be clearly established because of intra-abdominal dissemination. No distinctive morphological features were identified for the cohort of tumors defined by 1530ins6 KIT mutations. Most of the tumors showed predominant spindle cell morphology, and a few cases had epithelioid or pleomorphic histological features. Following previously published criteria based on tumor size and mitotic rate, 22 of 26 (85%) tumors were classified as malignant or potentially malignant, and 4 (15%) were classified as probably benign. A malignant clinical course was documented in 18 of 19 tumors from the malignant category. The survival times of 11 patients who died of disseminated GISTs ranged from 1 month to 105 months (median survival time, 26 months). In contrast, 2 of 4 GISTs assigned as probably benign tumors with follow-up information had long disease-free survival. GISTs carrying 1530ins6 occur exclusively in the intestinal location, and a great majority of these tumors follow a malignant course.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14691917     DOI: 10.1016/s0046-8177(03)00407-6

Source DB:  PubMed          Journal:  Hum Pathol        ISSN: 0046-8177            Impact factor:   3.466


  17 in total

1.  The location of KIT and PDGFRA gene mutations in gastrointestinal stromal tumours is site and phenotype associated.

Authors:  R Penzel; S Aulmann; M Moock; M Schwarzbach; R J Rieker; G Mechtersheimer
Journal:  J Clin Pathol       Date:  2005-06       Impact factor: 3.411

2.  Improved detection of KIT exon 11 duplications in formalin-fixed, paraffin-embedded gastrointestinal stromal tumors.

Authors:  Jerzy Lasota; Bartosz Wasag; Sonja E Steigen; Janusz Limon; Markku Miettinen
Journal:  J Mol Diagn       Date:  2007-02       Impact factor: 5.568

Review 3.  An update on molecular genetics of gastrointestinal stromal tumours.

Authors:  L Tornillo; L M Terracciano
Journal:  J Clin Pathol       Date:  2006-06       Impact factor: 3.411

Review 4.  Gastrointestinal stromal tumours: origin and molecular oncology.

Authors:  Christopher L Corless; Christine M Barnett; Michael C Heinrich
Journal:  Nat Rev Cancer       Date:  2011-11-17       Impact factor: 60.716

5.  Correlation of kinase genotype and clinical outcome in the North American Intergroup Phase III Trial of imatinib mesylate for treatment of advanced gastrointestinal stromal tumor: CALGB 150105 Study by Cancer and Leukemia Group B and Southwest Oncology Group.

Authors:  Michael C Heinrich; Kouros Owzar; Christopher L Corless; Donna Hollis; Ernest C Borden; Christopher D M Fletcher; Christopher W Ryan; Margaret von Mehren; Charles D Blanke; Cathryn Rankin; Robert S Benjamin; Vivien H Bramwell; George D Demetri; Monica M Bertagnolli; Jonathan A Fletcher
Journal:  J Clin Oncol       Date:  2008-10-27       Impact factor: 44.544

6.  Current trends in the epidemiological and pathological characteristics of gastrointestinal stromal tumors in Korea, 2003-2004.

Authors:  Mee-Yon Cho; Jin Hee Sohn; Joon Mee Kim; Kyoung-Mee Kim; Young Su Park; Woo Ho Kim; Jin Sook Jung; Eun Sun Jung; So-Young Jin; Dae Young Kang; Jae Bok Park; Ho Sung Park; You Duck Choi; Sun Hee Sung; Young-Bae Kim; Hogeun Kim; Young-Kyung Bae; Miseon Kang; Hee Jin Chang; Yang Seok Chae; Hee Eun Lee; Do Youn Park; Youn Soo Lee; Yun Kyung Kang; Hye Kyung Kim; Hee-Kyung Chang; Soon Won Hong; Young Hee Choi; Okran Shin; MiJin Gu; Youn Wha Kim; Gwang Il Kim; Sei Jin Chang
Journal:  J Korean Med Sci       Date:  2010-05-24       Impact factor: 2.153

7.  Pitfalls in mutational testing and reporting of common KIT and PDGFRA mutations in gastrointestinal stromal tumors.

Authors:  Sabine Merkelbach-Bruse; Wolfgang Dietmaier; Laszlo Füzesi; Andreas Gaumann; Florian Haller; Julia Kitz; Antje Krohn; Gunhild Mechtersheimer; Roland Penzel; Hans-Ulrich Schildhaus; Regine Schneider-Stock; Ronald Simon; Eva Wardelmann
Journal:  BMC Med Genet       Date:  2010-07-04       Impact factor: 2.103

Review 8.  [Gastrointestinal stromal tumors: evolution of a tumor concept from unclassifiable neoplasms to targeted molecular therapy].

Authors:  A Agaimy; R Schneider-Stock
Journal:  Pathologe       Date:  2010-03       Impact factor: 1.011

9.  [Pathology and molecular biology of gastrointestinal stromal tumors (GIST)].

Authors:  H-U Schildhaus; S Merkelbach-Bruse; R Büttner; E Wardelmann
Journal:  Radiologe       Date:  2009-12       Impact factor: 0.635

10.  Mechanisms of sunitinib resistance in gastrointestinal stromal tumors harboring KITAY502-3ins mutation: an in vitro mutagenesis screen for drug resistance.

Authors:  Tianhua Guo; Mihai Hajdu; Narasimhan P Agaram; Hiroko Shinoda; Darren Veach; Bayard D Clarkson; Robert G Maki; Samuel Singer; Ronald P Dematteo; Peter Besmer; Cristina R Antonescu
Journal:  Clin Cancer Res       Date:  2009-10-27       Impact factor: 12.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.